Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech firm, is pioneering off-the-shelf, genetically unmodified T cell therapies in oncology, neurology, and virology. At the Longwood Spring MIT Conference, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, discussed the transformative potential of Tevogen's T cell technology. Key highlights include the company's efforts to mainstream T cell therapy, reduce manufacturing costs, and eliminate side effects associated with CAR-T therapies. Mehta emphasized Tevogen's capability to produce hundreds of doses from a single donor and its strategy to develop T cell therapies for large patient populations, including those affected by Long COVID and multiple sclerosis. The company's approach focuses on speed, cost efficiency, and innovative pricing strategies, positioning Tevogen as a model for the industry.
- Tevogen is developing off-the-shelf, genetically unmodified T cell therapies.
- The company aims to reduce manufacturing costs and eliminate CAR-T therapy side effects.
- Tevogen has produced hundreds of doses from a single donor in a clinical trial.
- Focus on large patient populations, including Long COVID and multiple sclerosis.
- Innovative pricing strategies and large-scale manufacturing plans.
- The full potential of T cell-based therapies remains untapped due to cost and reimbursement imbalances.
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of Mittul Mehta, Tevogen’s Chief Information Officer and Head of Tevogen.AI, at the Longwood Spring MIT Conference. Mehta emphasized the transformative potential of Tevogen Bio’s innovative T cell technology and the company’s groundbreaking approach to overcoming industry challenges.
Key Points from Mehta’s Commentary
Realizing the Full Potential of T Cell Therapies. Mehta emphasized that the full potential of T cell-based therapies remains untapped due to various limitations, including the imbalance between the cost of manufacturing and reimbursement rates.
Development of a New Class of T Cell Therapies. Mehta highlighted that Tevogen is leading the development of a potential new class of T cell therapies for treatment of acute viral infections, long-term consequences of viral infections such as Long COVID, viral- and non-viral-induced cancers, and certain neurological disorders, including multiple sclerosis.
Overcoming Common Challenges Faced by the Industry with the CAR-T Approach. Mehta discussed that product candidates from company’s proprietary ExacTcell™ platform are designed to:
- Mainstream cell therapy through off-the-shelf outpatient administration focusing on diseases that impact large patient populations.
- Eliminate side effects associated with traditional CAR-based T cell therapies.
- Significantly reduce manufacturing costs. Mehta pointed out that Tevogen has achieved the production of hundreds of doses from a single donor for its recently completed clinical trial.
Industry’s First Attempt to Develop T Cell-Based Therapies for Large Patient Populations. Mehta discussed how Tevogen designed its entire business approach, from future pricing strategies to large-scale cell therapy manufacturing plans. He highlighted that speed and cost efficiency are critical to the future of the industry, and that Tevogen believes it is poised to serve as a model for others.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; Tevogen’s manufacturing plans; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this presentation and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
These factors include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the outcome of any legal proceedings that may be instituted against Tevogen related to the Business Combination; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; Tevogen’s limited operating history; and those factors discussed in Tevogen’s Annual Report on Form 10-K and other filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen Bio's new class of T cell therapies?
Who discussed Tevogen Bio's strategy at the Longwood Spring MIT Conference?
How is Tevogen Bio addressing the limitations of current T cell therapies?
What are Tevogen Bio's plans for large-scale cell therapy manufacturing?
What is Tevogen Bio's stock symbol?
